Fernandez-Sanchez A, Hernandez-Sanchez A, de Ramon C, Chillon M, Vidriales M, Baile-Gonzalez M
Biomedicines. 2024; 12(10).
PMID: 39457651
PMC: 11504412.
DOI: 10.3390/biomedicines12102339.
Saugues S, Lambert C, Daguenet E, Roth-Guepin G, Huguet F, Cony-Makhoul P
Haematologica. 2024; 109(9):2893-2907.
PMID: 38695126
PMC: 11367206.
DOI: 10.3324/haematol.2023.284860.
Iriyama N, Iwanaga E, Kimura Y, Watanabe N, Ishikawa M, Nakayama H
Int J Hematol. 2024; 120(1):60-70.
PMID: 38587692
DOI: 10.1007/s12185-024-03758-4.
Iezza M, Cortesi S, Ottaviani E, Mancini M, Venturi C, Monaldi C
Cells. 2023; 12(13).
PMID: 37443737
PMC: 10341256.
DOI: 10.3390/cells12131703.
Adattini J, Gross A, Doo N, McLachlan A
Pharmacol Res Perspect. 2022; 10(5):e01005.
PMID: 36106342
PMC: 9475133.
DOI: 10.1002/prp2.1005.
[Combination of socio-demographic and clinical co-variates for predicting treatment responses and outcomes in patients with chronic myeloid leukemia in the chronic phase].
Zhang X, Qin Y, Lai Y, Shi H, Huang X, Jiang Q
Zhonghua Xue Ye Xue Za Zhi. 2022; 43(1):54-62.
PMID: 35231994
PMC: 8980668.
DOI: 10.3760/cma.j.issn.0253-2727.2022.01.011.
Impact of BCR-ABL1 Transcript Type on Outcome in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors: A Pairwise and Bayesian Network Meta-Analysis.
Chen K, Ruan Y, Tian K, Xiong P, Xia N, Li J
Front Oncol. 2022; 12:841546.
PMID: 35223524
PMC: 8867088.
DOI: 10.3389/fonc.2022.841546.
Which Tyrosine Kinase Inhibitors Should Be Selected as the First-Line Treatment for Chronic Myelogenous Leukemia in Chronic Phase?.
Ono T
Cancers (Basel). 2021; 13(20).
PMID: 34680265
PMC: 8534191.
DOI: 10.3390/cancers13205116.
Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network.
Specchia G, Pregno P, Breccia M, Castagnetti F, Monagheddu C, Bonifacio M
Front Oncol. 2021; 11:739171.
PMID: 34513714
PMC: 8427308.
DOI: 10.3389/fonc.2021.739171.
[Clinical characteristics, treatment pattern, and outcomes in newly diagnosed patients with chronic myeloid leukemia in the chronic phase by age].
Peng N, Dou X, Yu L, Qin Y, Shi H, Lai Y
Zhonghua Xue Ye Xue Za Zhi. 2021; 42(2):101-108.
PMID: 33858039
PMC: 8071670.
DOI: 10.3760/cma.j.issn.0253-2727.2021.02.003.
First-generation vs second-generation tyrosine kinase inhibitors: which is best at diagnosis of chronic phase chronic myeloid leukemia?.
Oehler V
Hematology Am Soc Hematol Educ Program. 2020; 2020(1):228-236.
PMID: 33275713
PMC: 7727559.
DOI: 10.1182/hematology.2020000108.
The EUTOS long-term survival score predicts disease-specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice-based cohort.
Sato E, Iriyama N, Tokuhira M, Takaku T, Ishikawa M, Nakazato T
Cancer Med. 2020; 9(23):8931-8939.
PMID: 33037866
PMC: 7724301.
DOI: 10.1002/cam4.3516.
The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia.
Pfirrmann M, Clark R, Prejzner W, Lauseker M, Baccarani M, Saussele S
Leukemia. 2020; 34(8):2138-2149.
PMID: 32601376
PMC: 7387299.
DOI: 10.1038/s41375-020-0931-9.
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.
Hochhaus A, Baccarani M, Silver R, Schiffer C, Apperley J, Cervantes F
Leukemia. 2020; 34(4):966-984.
PMID: 32127639
PMC: 7214240.
DOI: 10.1038/s41375-020-0776-2.
Validation of the EUTOS Long-Term Survival Score in Chinese Chronic Myeloid Leukemia Patients Treated with Imatinib: A Multicenter Real-World Study.
Yang X, Bai Y, Shi M, Zhang W, Niu J, Wu C
Cancer Manag Res. 2020; 12:1293-1301.
PMID: 32110103
PMC: 7039071.
DOI: 10.2147/CMAR.S237467.
Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP.
Baccarani M, Abruzzese E, Accurso V, Albano F, Annunziata M, Barulli S
Blood Adv. 2019; 3(24):4280-4290.
PMID: 31869412
PMC: 6929396.
DOI: 10.1182/bloodadvances.2019000865.
New Approaches and Treatment Combinations for the Management of Chronic Myeloid Leukemia.
Westerweel P, Te Boekhorst P, Levin M, Cornelissen J
Front Oncol. 2019; 9:665.
PMID: 31448223
PMC: 6691769.
DOI: 10.3389/fonc.2019.00665.
Imatinib is still recommended for frontline therapy for CML.
Hantel A, Larson R
Blood Adv. 2018; 2(24):3648-3652.
PMID: 30587493
PMC: 6306882.
DOI: 10.1182/bloodadvances.2018018614.
